Objective: Cell-free DNA (cfDNA) screening for aneuploidy was clinically introduced in 2011. We aim to focus on the follow-up information from a single tertiary center undergoing genome-wide cfDNA screening to evaluate this technology.
methods. 4 In recent years, the cfDNA screening was extended to detect whole-genome abnormalities, although its clinical utilization is still questionable, and more validating data are still needed.
14 Opinion statements and guidelines by national and international professional societies support the clinical use of cfDNA screening in pregnant women. 2 The Chinese government has published its policy statement in 2016, which recommends the use of this method in screening the aneuploidies including trisomies 13, 18, and 21. According to these guidelines stating criteria for the screening and management, cfDNA screening has been widely occupied in America, Europe, and Asia. [15] [16] [17] [18] [19] [20] Hundreds of thousands of tests have been performed worldwide, and large number of reports have been published to summarize the clinical performance of cfDNA screening. Among them, however, very few large-scale studies reporting on >10 000
women were achieved in actual clinical settings and outside a research protocol, 15, 19, 21, 22 with most of them reporting on <1000 total women. 23, 24 On the other side, most publications supported by commercial laboratories performing cfDNA screening had a large sample size, while less focuses were put on the detailed clinical outcomes, especially in cases with low-risk results, which accounts for the major part of cfDNA screening. 3, 4, 25, 26 Thus, large-scale follow-up information showing detailed outcomes of all the cfDNA screening results is yet to be summarized, which is informative to comprehensively evaluate this screening tool in the whole process of perinatal care in actual clinical settings.
In this work, we presented the clinical data of a cohort consisting 32 431 cfDNA screening cases performed at a single tertiary center in
China during the past practice from 2011 to 2016. We summarized all the information including the cfDNA screening results, the confirmatory invasive test results, and the detailed follow-up information to assess the performance of cfDNA screening for chromosomes 21, 18, 13, X, and Y in our center and to analyze the clinical outcomes following high-risk, low-risk, and no call results. We also reported on our early experience of genome-wide cfDNA screening in the subgroup of our study population that elected to have this form of screening.
2 | METHODS
| Recruitment criteria
From August 2011 to December 2016, 32 431 cases were recruited in this study from the Medical Genetics Center in the Affiliated Obstetrics and Gynecology Hospital with Nanjing Medical University, a tertiary center for prenatal diagnosis and genetic counseling.
Participants must be at least 12 weeks of gestation with a singleton pregnancy. Women undergoing cfDNA screening included low-risk women, and women at increased risk of aneuploidy due to advanced maternal (≥35), previous child with aneuploidy, maternal serum screening high risk (cut-off 1/270), and maternal serum screening intermediate risk (cut-off 1/1000-1/270). All participants underwent pretest counseling and signed informed written consent before blood collection. This study was approved by the institutional review board of the Affiliated Obstetrics and Gynecology Hospital of Nanjing Medical University.
| CfDNA screening
Five-milliliter peripheral blood of pregnant women was collected by EDTA anticoagulant tube and centrifuged within 8 hours to extract the plasma. The plasma was frozen and sent to BGI-Health, and whole-genome massively parallel shotgun sequencing was performed in all cases. The detailed technical procedure was described previously. 22 In brief, libraries were constructed and sequenced with 36-cycle single-end multiplex sequencing on Illumina HiSeq2000 platforms (Illumina, San Diego, California). Sequencing reads were trimmed and aligned to a universal unique read set, incised from the human reference genome (hg18, NCBI build 36). Quality control criteria included minimum unique read number and the GC content range. Analysis was performed for all samples on chromosomes 13, 18, 21, X, and Y. 27 Starting from 2012, screening for other genomewide rare autosomal aneuploidies (RAT) and subchromosome copy number variants (CNV) 28 was added to the aspect of screening as an additional service, and women need to consent to this separately to the common aneuploidies. Fetal fraction of male fetuses was calculated based on the Y chromosome fraction 27 but not provided in the What's already known about this topic?
• Noninvasive prenatal screening based on cell-free DNA (cfDNA) has become integrated into clinical practice for detection of common fetal chromosomal aneuploidies. In addition, genome-wide cfDNA screening has also been available although its routine use is still controversial. However, comprehensive evaluation using large-scale follow-up information for cfDNA screening, especially for the low-risk cases, is still limited.
What does this study add?
• We report the detailed clinical follow-up of 32 431
cfDNA screening cases performed in our tertiary center.
• In the group of women who received high-risk cfDNA results but did not have confirmatory diagnostic testing, 23% proceeded directly to termination of pregnancy, 30% terminated due to ultrasound abnormalities, and 15% experienced an unintended pregnancy loss.
• In the group of 31 958 women who received low-risk cfDNA results, 0.5% underwent diagnostic testing and three cases of false negative were confirmed.
• 
| Clinical follow-up
Pregnancies with low-risk cfDNA screening results were recommended for routine prenatal care; genetic counseling was offered if fetal abnormalities were detected by routine ultrasound examination.
These cases were interviewed at 3 months after delivery according to the guideline published by Chinese government, and information, including the ultrasound examination, pregnancy outcomes, date of birth, sex, newborn physical examination results, and neonatal/fetal cytogenetic analysis, were recorded. Pregnancies with high-risk cfDNA results were recommended for confirmatory invasive prenatal diagnosis using amniocentesis following karyotyping and/or chromosomal microarray analysis (CMA). These women were followed up within 3 months after we send the test reports, which was defined as the prenatal follow-up. Information, including cytogenetic test results, ultrasound examination results, and pregnancy outcomes, were collected. If any of these women chose to continue their pregnancies, a second follow-up, for further retrieving their pregnancy outcomes, was conducted at 3 months after delivery, which was defined as the postnatal follow-up. The cases with test failure were also followed-up at 3 months after delivery, and the interview contents were similar to that of low-risk cfDNA screening results.
The "true positive" was defined as those high-risk cfDNA results that were confirmed by prenatal or postnatal diagnostic genetic testing. The "false positive" was defined as high-risk cfDNA results that were shown to be euploid by follow-up invasive diagnostic genetic testing or based on clinical physical examination at birth (barring SCAs). The "true negative" was defined as low-risk cfDNA results con- 
| Statistical analysis
Statistical analysis between the different groups was performed using a chi-square (X 2 ) test or Fisher's exact test, and P values of ≤0.05 were considered statistically significant.
| RESULTS
Data from a total of 32 431 cases were included in this study, which mainly consists of women from Eastern China. (Table S2 and Figure 2 ). Furthermore, in the RAT cases without prenatal diagnosis, three opted for TOP due to abnormal ultrasound findings (Table S3 ). (Table 3 ). In the other 163 cases, the women chose to have prenatal diagnosis by amniocentesis. One hundred and fifty-eight women chose invasive prenatal testing because of anxiety, and all of them had normal fetal karyotypes and gave live births. The other five were due to fetal anatomical anomalies detected by ultrasound. Notably, two of them had a result of T21 karyotypes and chose TOP, which revealed false negative cases for cfDNA screening ( Figure 3 ).
| Test failures
Our cohort also included 34 cases who encountered a test failure, which were more suspected to an abnormal outcome according to previous reports. Therefore, a detailed follow-up was also conducted for these cases. Results revealed that 28 of them had a live birth with a normal neonatal physical examination. Four women underwent TOP, and the indications include the maternal physical conditions (no further information was available during the follow-up), abnormal fetal ultrasound result, and an invasive diagnostic result of T21 ( Figure S1 ).
| Performance of cfDNA screening
On the basis of the cfDNA screening results and the outcome data available, we calculate the performance of this screening method in detection of aneuploidies (Table 4) . For T21, T18, and T13, the sensitivity was 97.45%, 100%, and 100%; specificity was 99.96%, 99.94%, and 99.96%; PPV was 92%, 58.97%, and 23.08%; NPV was 99.99%, 100%, and 100%, respectively. As for SCA, it revealed a PPV of 49.12% based on the data we have (Table S4 ). Our results revealed high sensitivity and specificity for the common trisomies, which is comparable to studies from other countries. 3, 15, 29 As for the PPVs for detection of trisomies 21, 18, 13 and SCAs, our result revealed a comparable number for T21 and T18 to other studies, but the PPV for T13 was relatively lower in our population compared to others. 7, 15 This could be due to the low number of T13 cases detected in our study, which would increase the PPV variation. [30] [31] [32] Genome-wide cfDNA screening, including the screening for other chromosome abnormalities such as fetal CNV and RAT, has been available in recent years. 14, 33 However, the application of this extended cfDNA screening in clinic use is still controversial. The 2015 ACOG-SMFM committee opinion on cfDNA screening stated that "the screening for the microdeletions has not been validated in clinical studies," and "routine cell-free DNA screening for microdeletion syndromes should not be performed." 34 In a recent debate, the benefit and the limitation of this new screening method was discussed. 35 In our clinical practice, genome-wide cfDNA screening was performed from late 2012. Consistent with other reports, our screening and follow-up results revealed that this method is capable to detect fetal CNVs successfully but also caused a number of invasive tests that appeared to be unnecessary. Importantly, as the clinical consequences of these chromosome abnormalities may not be present at perinatal stage, such as mental retardation, a long-term follow-up and a complex genetic counseling would be desirable. During our and others' studies, a convincing genome-wide NIPS protocol for CNVs and RATs was still in development, and hence, the results should be interpreted with caution and are not considered robust performance statistics.
| DISCUSSION
However, our study would contribute to the clinical evaluation of genome-wide cfDNA screening. Some early lessons, such as high rate of declining confirmatory diagnosis for RATs, were obtained, which will help to achieve better genetic counseling in the future. One possible explanation is that most of these cases took place during 2011 to 2012, and these cases also had high-risk factors for aneuploidies such as high-risk serum screening results or advanced maternal age. They were not fully convinced by the low-risk cfDNA screening results and decided to take invasive testing for fully assurance. After 2012, the test accuracy of cfDNA screening had been repeatedly proven and more detailed pretest counseling was provided.
As a result, this situation had been greatly reduced. These cases reveal the importance of proper pretest and posttest counseling.
There are still several limitations existing in this study. First, although we made efforts to follow up all the cases, there were still 18.5% (5998/32 431) cases missing the pregnancy outcomes, and it is possible that the women in these cases refused to respond to our follow-up because of adverse pregnancy outcomes. In addition, in cases with a high-risk/atypical abnormality screening result who chose to continue their pregnancies, a long-term follow-up would be favorable, which was not done yet. Second, we were not able to obtain genetic explanation for the women with the discordant results between cfDNA screening and karyotype, which accounts for 28% of high-risk cfDNA results. Factors including confined placental mosaicism, 38, 39 fetal mosaicism, maternal chromosome abnormality, 40 vanishing twin, 25, 41 and fetal pathogenic CNV [42] [43] [44] had important roles in causing the discordance. In fact, most women thought that the normal fetal karyotyping results were enough and declined for further genetic testing; thus, it is difficult to obtain the DNA samples from the infants or the placenta to clarify the cause of the discordance.
Although some recent work stated it is unnecessary to extensively test the placental tissue, 30 we believe that these genetic information would be valuable for the improvement of both perinatal care and the technique, which could be collected in clinical practice in the future. Furthermore, our outcome results revealed a number of pregnancy loss and TOP in both high-risk and low-risk cfDNA results, in which we also failed to retrieve a genetic diagnosis for possible explanations. Thus, there could have been underascertainment of affected pregnancies.
In conclusion, our study summarized the clinical data of 32 431
cfDNA screening cases in China, including detailed follow-up informa- with clinical follow-up data, as the point previously stated. 45, 46 Above all, our results focused on the follow-up data for cfDNA screening and provided information that may help with result interpretation, patient counseling, and decision making in clinic.
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